B.R.A.I.N. Biotechnology Research and Information Network (BNN) AI Stock Analysis

• Market Cap: €41.84M
• Dividend Yield: N/A
• Average Volume (3M): 3.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: -4.90%
• EPS Growth: -69.80%
• Country: DE
• Employees: 296
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 21,847,494
• 10 Day Avg. Volume: 2,384
• 30 Day Avg. Volume: 3,145
• PEG Ratio: -0.31
• Price to Book (P/B): 7.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €6.90
• Price Target Upside: 255.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 43 Neutral
• Price Target: €2.00 ▲(3.09%Upside)

B.R.A.I.N. Biotechnology Research and Information Network currently faces substantial financial and market challenges. The most significant downside factors include poor financial performance and technical analysis indicators, which highlight operational inefficiencies and bearish market sentiment. Valuation concerns further depress the stock score due to negative earnings and lack of dividend yield.

B.R.A.I.N. Biotechnology Research and Information Network Business Overview & Revenue Model

Company Description

BRAIN Biotech AG researches, develops, produces, and markets enzymes, biocatalysts, microorganisms, and bioactive natural substances for chemical industries in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates in two segments, BioScience and BioIndustrial. It identifies and develops bioactive natural compounds, including sugar substitutes and taste modulators, and nature-based active ingredients for product development in the food, animal feed, skin care, cosmetics, and chemical industries. The company also identifies and develops optimized enzymes and biocatalysts for the production of food and beverages, and wound care preparations or lubricants, as well as for starch processing of bioethanol production; and microorganisms as the functional biomass for optimized industrial production processes, recycling of greenhouse gas CO2 as an industrial raw material, and extraction of precious and rare earth metals. It has strategic partnerships with AnalytiCon Discovery GmbH and Roquette to develop natural sweeteners and sweet taste enhancers. The company was formerly known as B.R.A.I.N. Biotechnology Research and Information Network AG and changed its name to BRAIN Biotech AG in April 2021. BRAIN Biotech AG was founded in 1993 and is headquartered in Zwingenberg, Germany.

How the Company Makes Money

BNN makes money through a diversified revenue model that includes product sales, licensing agreements, and collaborative partnerships. The company generates revenue by selling its proprietary microbial and enzyme-based products directly to industrial clients. Additionally, BNN enters into licensing agreements with companies seeking to utilize its patented technologies, providing a steady stream of royalty income. Strategic partnerships and collaborations with other biotech firms and research institutions also contribute to BNN's earnings, allowing the company to expand its reach and enhance its product offerings. These partnerships often involve joint development projects, where BNN provides its expertise in exchange for financial compensation or equity stakes in collaborative ventures.

B.R.A.I.N. Biotechnology Research and Information Network Financial Statement Overview

Summary

The company faces significant financial challenges with persistent net losses, negative cash flows, and low profitability margins. Negative operating cash flow and high debt-to-equity ratio indicate financial instability, despite some revenue growth and recent improvements in debt management.

Income Statement

The company shows a concerning trajectory with consistent net losses and declining profit margins. The TTM data indicates a negative EBIT and EBITDA, suggesting operational inefficiencies. Revenue has shown some growth over the years, but the net profit margin remains negative, indicating profitability challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, but recent TTM data suggests no total debt, indicating improvement in leverage. The equity ratio is low, reflecting potential risk. Historical stockholders' equity decline suggests financial instability.

Cash Flow

Operating cash flow is negative, indicating difficulties in generating cash from operations. Free cash flow remains negative, though recent financing activities have improved liquidity. The consistent negative free cash flow to net income ratio highlights ongoing cash flow challenges.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	67.74M	54.63M	55.34M	49.51M	38.39M	38.23M
Gross Profit	23.11M	30.33M	3.47M	27.45M	21.57M	21.20M
EBITDA	-4.67M	-4.23M	-1.98M	-1.30M	2.01M	-4.92M
Net Income	-15.16M	-11.13M	-8.28M	-6.34M	-4.68M	-9.02M
Balance Sheet
Total Assets	80.33M	88.74M	70.94M	77.99M	77.74M	72.15M
Cash, Cash Equivalents and Short-Term Investments	17.82M	27.29M	5.41M	8.80M	24.65M	19.05M
Total Debt	0.00	12.80M	4.66M	3.04M	2.64M	30.60M
Total Liabilities	70.02M	74.85M	47.92M	43.74M	35.91M	46.01M
Stockholders Equity	9.04M	12.62M	21.77M	29.64M	38.78M	20.79M
Cash Flow
Free Cash Flow	-8.48M	-5.31M	-6.86M	-7.57M	-5.17M	-7.63M
Operating Cash Flow	-6.92M	-3.58M	-4.22M	-1.49M	-3.91M	-4.77M
Investing Cash Flow	-1.95M	-1.69M	562.00K	-12.69M	-2.18M	-4.47M
Financing Cash Flow	21.14M	26.99M	459.00K	-1.97M	11.57M	13.09M

B.R.A.I.N. Biotechnology Research and Information Network Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BNN, the sentiment is Neutral. The current price of 1.94 is above the 20-day moving average (MA) of 1.92, below the 50-day MA of 2.02, and below the 200-day MA of 2.64, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.02 is Neutral, neither overbought nor oversold. The STOCH value of 52.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:BNN.

B.R.A.I.N. Biotechnology Research and Information Network Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.52B	0.21	-63.76%	2.30%	16.15%	0.89%
BNN	43 Neutral	€41.84M	―	-111.86%	―	-4.90%	-69.80%
0R6U	―	€19.19M	―	-288.87%	―	―	―
0DOL	―	€15.25M	541.55	-22.41%	―	―	―
0EL9	―	€17.97M	25.86	3.25%	3.03%	―	―
0QW5	―	€222.29M	―	-78.11%	―	―	―
T5O0	―	€520.96K	―		―	―	―